The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).

Steven M. Horwitz,Jasminder Soto,Hagop Youssoufian,Deborah Lloyd,Ngocdiep T. Le

The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).

2018

Steven M. Horwitz
Jasminder Soto
Hagop Youssoufian
Deborah Lloyd
Ngocdiep T. Le

TPS7590Background: Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-δ and PI3K-γ being developed for the treatment of hematologic malignancies. In preclinical investigations,...

Keywords:

Refractory Peripheral T-cell Lymphoma
Phases of clinical research
Oncology
Pathology
Duvelisib
Internal medicine
Medicine
in patient
dual inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations